公开(公告)号：US20150010475A1

公开(公告)日：2015-01-08

申请号：US14369741

申请日：2012-12-31

Applicant: STC. UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  David S. Peabody ,  Walker Kip Wharton ,  Bryce Chackerian ,  Carlee Erin Ashley ,  Cheryl L. Willman ,  Eric C. Carnes ,  Katherine Epler ,  Robert Eric Castillo

IPC: A61K47/48 ,  C12N15/113 ,  C12N15/11 ,  C07K7/06 ,  A61K31/704

CPC classification number: A61K31/704 ,  A61K47/62 ,  A61K47/64 ,  A61K47/6911 ,  C07K7/06 ,  C12N15/111 ,  C12N15/113

Abstract: The present invention relates to the use of which are attached or anchored phospholipid biolayers further modified by CRLF-2 and CD 19 binding peptides which may be used for delivering pharmaceutical cargos, to cells expressing CRLF-2 and CD 19, thereby treating cancer, in particular, acute lymphoblastic leukemia (ALL), including (B-precursor acute lymphoblastic leukemia (B-ALL). Novel CRLF-2 binding peptides and CLRF-2 and CD19-binding viral-like particles (VLPs) useful in the treatment of cancer, including ALL are also provided.

Abstract translation: 本发明涉及其用途，其可用于将可用于递送药物载体的CRLF-2和CD19结合肽进一步修饰的磷脂生物层结合到表达CRLF-2和CD19的细胞中，从而治疗癌症 特别是急性淋巴细胞白血病（ALL），包括（B-前体急性成淋巴细胞白血病（B-ALL）），用于治疗癌症的新型CRLF-2结合肽和CLRF-2和CD19结合病毒样颗粒（VLP） ，也包括ALL。

公开(公告)号：US20160338954A1

公开(公告)日：2016-11-24

申请号：US15023110

申请日：2014-09-18

Applicant: STC. UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  Yu-Shen Lin

IPC: A61K9/127 ,  A61K38/16 ,  C12N15/88 ,  A61K39/395 ,  A61K9/51 ,  A61K31/7088 ,  A61K38/43

CPC classification number: A61K9/1271 ,  A61K9/14 ,  A61K9/5115 ,  A61K9/5123 ,  A61K31/7088 ,  A61K38/16 ,  A61K38/43 ,  A61K39/395 ,  B82Y5/00 ,  B82Y15/00 ,  C12N15/88

Abstract: In one aspect, the invention provides novel monodisperse, colloidally-stable, torroidal mesoporous silica nanoparticles (TMSNPs) which are synthesized from ellipsoid-shaped mesoporous silica nanoparticles (MSNPs) which are prepared using an ammonia base-catalyzed method under a low surfactant conditions. Significantly, the TMSNPs can be loaded simultaneously with a small molecule active agent, a siRNA, a mRNA, a plasmid and other cargo and can be used in the diagnosis and/or treatment of a variety of disorders, including a cancer, a bacterial infection and/or a viral infection, among others. Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.

Abstract translation: 一方面，本发明提供了由在低表面活性剂条件下使用氨碱催化法制备的椭圆形介孔二氧化硅纳米粒子（MSNP）合成的新型单分散，胶体稳定的环形介孔二氧化硅纳米粒子（TMSNP）。 值得注意的是，TMSNPs可以与小分子活性剂，siRNA，mRNA，质粒和其他货物同时加载，并且可以用于诊断和/或治疗各种疾病，包括癌症，细菌感染 和/或病毒感染等。 还提供了相关的原细胞，药物组合物和治疗和诊断方法。

公开(公告)号：US20160151482A1

公开(公告)日：2016-06-02

申请号：US14781765

申请日：2014-04-02

Applicant: STC. UNM ,  SANDIA CORPORATION

Inventor： Eric C. Carnes ,  C. Jeffrey Brinker ,  Carlee Erin Ashley

IPC: A61K39/39 ,  A61K9/14 ,  A61K9/51

CPC classification number: A61K39/39 ,  A61K9/127 ,  A61K9/146 ,  A61K9/5115 ,  A61K9/5184 ,  A61K31/365 ,  A61K38/19 ,  A61K39/0208 ,  A61K39/07 ,  A61K39/08 ,  A61K45/06 ,  A61K47/6923 ,  A61K47/6929 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2300/00

Abstract: The present invention relates to mesoporous alum nanoparticles which can be used as a universal platform for antigen adsorption, presentation and delivery to provide immune compositions, including vaccines and to generate an immune response (preferably, both humoral and cell mediated immune response), preferably a heightened immune response to the presentation of one or more antigens to a patient or subject.

Abstract translation: 本发明涉及介孔矾纳米颗粒，其可用作抗原吸附，呈递和递送的通用平台，以提供免疫组合物，包括疫苗和产生免疫应答（优选体液和细胞介导的免疫应答），优选为 增加对一种或多种抗原呈递给患者或受试者的免疫应答。

公开(公告)号：US10130916B1

公开(公告)日：2018-11-20

申请号：US15273445

申请日：2016-09-22

Applicant: Sandia Corporation ,  THE REGENTS OF THE UNIVERSITY OF NEW MEXICO

Inventor： Susan Rempe ,  C. Jeffrey Brinker ,  David Michael Rogers ,  Ying-Bing Jiang ,  Shaorong Yang

IPC: B01D69/04 ,  B01D67/00 ,  B01D71/02 ,  B01D63/06 ,  B01D69/10 ,  C23C16/02 ,  C23C16/04 ,  C23C16/455

Abstract: The present disclosure is directed to biomimetic membranes and methods of manufacturing such membranes that include structural features that mimic the structures of cellular membrane channels and produce membrane designs capable of high selectivity and high permeability or absorptivity. The membrane structure, material and chemistry can be selected to perform liquid separations, gas separation and capture, ion transport and adsorption for a variety of applications.

公开(公告)号：US20200276286A1

公开(公告)日：2020-09-03

申请号：US16647245

申请日：2018-09-13

Applicant: Rita E. Serda ,  C. Jeffrey Brinker ,  Jacob Ongudi Agola ,  Jimin Guo ,  Sarah Adams ,  STC.UNM

Inventor： Rita E. Serda ,  C. Jeffrey Brinker ,  Jacob Ongudi Agola ,  Jimin Guo ,  Sarah Adams

IPC: A61K39/00 ,  A61K39/39

Abstract: A silicified cell replica includes a silicified cell or a silicified subcellular fragment. The silicified cell replica may be used to induce an immunological response, treat a bacterial infection, or treat a patient with cancer.

公开(公告)号：US20180299357A1

公开(公告)日：2018-10-18

申请号：US15950979

申请日：2018-04-11

Applicant: National Technology & Engineering Solutions of Sandia, LLC ,  STC.UNM

Inventor： Bryan J. Kaehr ,  C. Jeffrey Brinker ,  Jason L. Townson

IPC: G01N1/28 ,  C08K3/36 ,  C12N11/14

Abstract: The present invention is directed to the use of silicic acid to transform biological materials, including cellular architecture into inorganic materials to provide biocomposites (nanomaterials) with stabilized structure and function. In the present invention, there has been discovered a means to stabilize the structure and function of biological materials, including cells, biomolecules, peptides, proteins (especially including enzymes), lipids, lipid vesicles, polysaccharides, cytoskeletal filaments, tissue and organs with silicic acid such that these materials may be used as biocomposites. In many instances, these materials retain their original biological activity and may be used in harsh conditions which would otherwise destroy the integrity of the biological material. In certain instances, these biomaterials may be storage stable for long periods of time and reconstituted after storage to return the biological material back to its original form. In addition, by exposing an entire cell to form CSCs, the CSCs may function to provide a unique system to study enzymes or a cascade of enzymes which are otherwise unavailable.

公开(公告)号：US10605705B2

公开(公告)日：2020-03-31

申请号：US15950979

申请日：2018-04-11

Applicant: National Technology & Engineering Solutions of Sandia, LLC ,  STC.UNM

Inventor： Bryan J. Kaehr ,  C. Jeffrey Brinker ,  Jason L. Townson

IPC: G01N1/28 ,  C08K3/36 ,  C12N11/14

Abstract: The present invention is directed to the use of silicic acid to transform biological materials, including cellular architecture into inorganic materials to provide biocomposites (nanomaterials) with stabilized structure and function. In the present invention, there has been discovered a means to stabilize the structure and function of biological materials, including cells, biomolecules, peptides, proteins (especially including enzymes), lipids, lipid vesicles, polysaccharides, cytoskeletal filaments, tissue and organs with silicic acid such that these materials may be used as biocomposites. In many instances, these materials retain their original biological activity and may be used in harsh conditions which would otherwise destroy the integrity of the biological material. In certain instances, these biomaterials may be storage stable for long periods of time and reconstituted after storage to return the biological material back to its original form. In addition, by exposing an entire cell to form CSCs, the CSCs may function to provide a unique system to study enzymes or a cascade of enzymes which are otherwise unavailable.

公开(公告)号：US20180169009A1

公开(公告)日：2018-06-21

申请号：US15577572

申请日：2016-06-01

Applicant: Patrick JOHNSON ,  C. Jeffrey BRINKER ,  Eric CARNES ,  Graham TIMMINS ,  Pavan MUTTIL ,  STC.UNM

Inventor： Patrick Johnson ,  C. Jeffrey Brinker ,  Eric Carnes ,  Graham Timmins ,  Pavan Muttil

IPC: A61K9/00 ,  A61K9/16 ,  A61K47/54 ,  C08L23/22 ,  A61K9/12 ,  A61K9/127

CPC classification number: A61K9/0073 ,  A61K9/12 ,  A61K9/1271 ,  A61K9/1617 ,  A61K47/543 ,  C08L23/22

Abstract: This disclosure describes compositions, vaccine, and methods that involve a biocomposite material Generally, the biocomposite material includes a cell and a lipid-silica matrix at least partially encapsulating the cell. In some cases, the cell can be viable but not culturable (VBNC). In some cases, the lipid-silica matrix includes a dried sol and/or possesses ordered nanostructure.

公开(公告)号：US20180110831A1

公开(公告)日：2018-04-26

申请号：US15557000

申请日：2016-03-09

Applicant: STC.UNM

Inventor： C. Jeffrey Brinker ,  Eric C. Carnes ,  Carlee Erin Ashley ,  Jacob Ongundi Agola ,  Kimberly Butler ,  Christophe Theron

IPC: A61K38/17 ,  A61K47/64 ,  A61K47/69 ,  A61K9/51 ,  C07K14/705

CPC classification number: A61K38/1774 ,  A61K9/127 ,  A61K9/5115 ,  A61K9/5123 ,  A61K47/6425 ,  A61K47/6911 ,  B82Y5/00 ,  C07K14/70546

Abstract: The present invention is directed to protocells, which have a core and a lipid bilayer surrounding the core, with at least one CD47 molecule or an active fragment thereof in or conjugated to the lipid bilayer. The CD47 present on the lipid bilayer allows the protocell to evade phagocytosis by macrophages, and can be conjugated to the lipid bilayer via a crosslinker. The protocell can be loaded with a diagnostic or therapeutic cargo, such as a polypeptide, a nucleic acid, or a drug. The protocell can also include a targeting species for targeted delivery of the cargo to a cell. The protocell can also include an endosomolytic peptide, which promotes endosomal escape after uptake by the targeted cell. The protocells with CD47 on the lipid bilayer provide better circulation after in vivo administration compared to protocells without CD47, and are therefore particularly useful as a cargo delivery vehicle.

公开(公告)号：US09970000B2

公开(公告)日：2018-05-15

申请号：US14996048

申请日：2016-01-14

Applicant: National Technology & Engineering Solutions of Sandia, LLC ,  STC.UNM

Inventor： Bryan J. Kaehr ,  C. Jeffrey Brinker ,  Jason L. Townson

IPC: C12N11/14 ,  C08K3/36

CPC classification number: G01N1/2806 ,  C08K3/36 ,  C12N11/14 ,  G01N1/2853

Abstract: The present invention is directed to the use of silicic acid to transform biological materials, including cellular architecture into inorganic materials to provide biocomposites (nanomaterials) with stabilized structure and function. In the present invention, there has been discovered a means to stabilize the structure and function of biological materials, including cells, biomolecules, peptides, proteins (especially including enzymes), lipids, lipid vesicles, polysaccharides, cytoskeletal filaments, tissue and organs with silicic acid such that these materials may be used as biocomposites. In many instances, these materials retain their original biological activity and may be used in harsh conditions which would otherwise destroy the integrity of the biological material. In certain instances, these biomaterials may be storage stable for long periods of time and reconstituted after storage to return the biological material back to its original form. In addition, by exposing an entire cell to form CSCs, the CSCs may function to provide a unique system to study enzymes or a cascade of enzymes which are otherwise unavailable.